A trial design in which neither the participants nor the researchers assessing outcomes know who received the active treatment and who received a placebo (an inactive comparison) until the study has finished. Blinding reduces the risk that expectation or bias, from either the participant or the researcher, distorts the results, which is why double-blind, placebo-controlled trials are generally considered more reliable than open-label (unblinded) studies.
Peptides where this matters
-
PT-141 (Bremelanotide)Bremelanotide
No UK marketing authorisation found; authorised in the US. Selective melanocortin-4 receptor agonist studied for low sexual desire in women.
StrongNot licensed in the UK -
KisspeptinMetastin
Natural reproductive hormone studied in UK trials for low sexual desire and IVF egg maturation. No UK marketing authorisation identified.
LimitedNot licensed in the UK -
SermorelinSermorelin acetate
Synthetic growth-hormone-releasing hormone fragment studied in children with growth hormone deficiency. Not licensed in the UK; evidence is mainly from before 2000.
LimitedNot licensed in the UK
Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.